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Membrane Hsp70 expression in gliomas: 
a novel, hypoxia-related marker for primary glioblastoma 
 
1 Introduction 
 
1.1 Gliomas: definition, epidemiology, classification and molecular biomarkers  
  Primary brain tumors range from benign pilocytic astrocytomas to malignant glioblastoma 
multiforme. In contrast to brain metastatic tumors which are from tumors originated in other organs 
or tissues in body, primary brain tumor arise from different cells in brain, such as gliomas arise from 
glial cells (Pytel and Lukas, 2009). In United States, gliomas account for nearly 31% of all primary 
CNS (central nervous system) tumors and 61% of gliomas occur in temporal, frontal, parietal and 
occipital lobes (www.cbtrus.org. 2011) (Brem et al., 2005). The incidence rates for gliomas seem to 
be higher in males than in females and significant higher among whites than among blacks 
(www.cbtrus.org. 2011). The world health organization (WHO) classifies gliomas on the basis of 
histological features into four grades: grade I (pilocytic astrocytoma), grade II (diffuse astrocytoma), 
grade III (anaplastic astrocytoma), and grade IV (glioblastoma)(Louis et al., 2007). Glioblastoma 
(GBM, WHO grade IV) accounts for the majority (>50%) of gliomas (www.cbtrus.org. 2011) 
(Preusser et al., 2011). Anaplastic astrocytoma and GBM account for malignant gliomas which have 
worse clinical outcome. Despite improved combined therapeutic strategies, including surgical 
resection, radiation and chemotherapy, the median survival is 13.2 months to 16.8 months (median, 
14.6 months) for the cases of GBMs and 2 to 5 years for the cases of anaplastic gliomas (Preusser et 
al., 2011; Stupp et al., 2005; Wen and Kesari, 2008). 
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  On the basis of biologic and genetic differences, GBM can be subdivided into two subtypes: 
primary GBM (account for >90%) and secondary GBM (account for 10%) (Preusser et al., 2011). 
Primary GBMs occur more frequently in elder patients (median age, 64 years) (Preusser et al., 2011) 
and do not have previous history of low-grade precursors, they are characterized by epidermal 
growth factor receptor (EGFR) amplification and mutations, loss of heterozygosity of chromosome 
10q, deletion of phosphatase-and tensin-homolog-on-chromosome-ten (PTEN) and p16 deletion 
(Kleihues and Ohgaki, 1999; Preusser et al., 2011). Secondary GBMs occur in young patients 
(median age, 45 years) (Preusser et al., 2011) and arise from low-grade astrocytomas, they are 
characterized by mutations in the p53 gene, overexpression of the platelet-derived growth factor 
receptor (PDGFR), abnormalities in the p16 and retinoblastoma (Rb) pathways, and loss of 
heterozygosity of chromosome 10q (Kleihues and Ohgaki, 1999; Preusser et al., 2011; Wen and 
Kesari, 2008). Recently, the methylation status of O
6
-methylguanine methyltransferase (MGMT) 
gene promoter has emerged as a promosing prognostic and predictive biomarker for GBM patients 
treated with alkylating drugs like nitrosoureas or temozolomide (Hegi et al., 2005). After treatments 
with radiotherapy plus temozolomide, GBM patient without MGMT promoter methylation has a 
12.7-month overall survival and 5.9-month progression-free survival, patient having a methylated 
GBM has better overall survival (median, 21.7 months) and progression-free survival (median, 10.3 
months) (Hegi et al., 2005; Stupp et al., 2009). Meanwhile, in over 80% of all secondary GBM, 
mutations of the isocitrate dehydrogenase 1 (IDH1) and IDH2 (a lesser extent) genes, which are 
specific mutated on amino acid R132 for IDH1 and R172 for IDH2, have been identified (Parsons et 
al., 2008; Yan et al., 2009). At the same time, the precursors of secondary GBM, WHO grade II 
(88%) and grade III gliomas (78%), also show IDH1 or IDH2 mutation (Watanabe et al., 2009; Yan 
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et al., 2009). In contrast, only 5% of primary GBM, which do not have low-grade precursors, have 
been shown to have IDH1 or IDH2 mutation (Watanabe et al., 2009; Yan et al., 2009). This 
suggested that IDH1/2 mutation might be an early event in tumor development of secondary GBM 
(Watanabe et al., 2009; Yan et al., 2009). Furthermore, gene expression patterns of EGFR, NF1, 
PDGFR and IDH1 are used for subclassification of GBMs into proneural, neural, classical and 
mesenchymal subtypes. On the basis of this classification, GBM patients with tumor classified as 
classical and mesenchymal subtypes show better responses to aggressive treatments than GBM 
patients with tumor classified as proneural and neural subtypes (Verhaak et al., 2010). 
 
1.2 Microenvironment of malignant brain tumors 
 
  Tumor microenvironment in general is described by Judithe Leibovici as the tumor stroma, which 
contains distinct cell types as well as extracellular matrix, a variety of soluble molecules, 
constituting a complex organ-like structure which is involved in tumorigenesis (Leibovici et al., 
2011). Except proliferating malignant cancer cells, cancer stem cells, endothelial cells, pericytes, 
immune inflammatory cells, cancer associated fibroblasts and recruited stem/progenitor cells have 
already been described to contribute to the biology of non-glial tumors (Hanahan and Weinberg, 
2011). The brain tumor microenvironment recently also has been reviewed(Charles et al., 2011). In 
brain tumor microenvironment, not only distinct cell types but also the intercellular cross-talk may 
contribute to the formation, invasion, progression and therapy-responses of brain tumors (Charles et 
al., 2011).  
 
 - 11 - 
1.2.1 Glioma stem cells 
  In 1997, Bonnet and Dick published a conclusive conception of cancer stem cells for the first time 
in Nature Medicine (Bonnet and Dick, 1997). In acute myeloid leukemia, they defined 
CD34+CD38- sorted cells as cancer stem cells (Bonnet and Dick, 1997). In brain tumor, concept of 
cancer stem cells is used to describe a relatively small cell subpopulation with characteristics of self 
renewal and differentiation, which has similarities to normal neural stem cells but resides in tumors 
(Reya et al., 2001). Since 2004, glioma stem cells were isolated by CD133 positive-sorting and 
showed neurosphere-like morphology within growth factors (Singh et al., 2004). They have been 
thought as the most tumorigenic component in gliomas，only hundreds of glioma stem cells showed 
the ability of tumor formation (Singh et al., 2004; Stiles and Rowitch, 2008). However, other groups 
show that CD133 expression is not limited to glioma stem cells and can be regulated by hypoxia via 
HIF-1alpha (Soeda et al., 2009). Surprisingly, CD133 negative cells also have been shown to have 
the ability of tumor formation (Lottaz et al., 2010). Moreover, with the passaging and culture in vivo, 
CD133 negative glioma cells may increase CD133 expression and finally give rise to CD133 
positive tumors (Wang et al., 2008). By now, glioma stem cells are defined as a neurosphere-like 
population with the ability of self-renewal and differentiation into neurons, astrocytes and 
oligodendrocytes in vitro and the ability of tumor formation (Jordan, 2009), but these criteria are also 
been challenged (Barrett et al., 2012). On the other hand, it is hard to say which cell type can be 
served as the origin for glioma stem cells among mature dedifferentiated glia, “restricted” neural 
progenitors and multipotent neural progenitors (Stiles and Rowitch, 2008). On the clinical side, 
glioma stem cells are suggested to contribute to radioresistance and chemoresistance, resulting in the 
maintenance and recurrence of gliomas (Bao et al., 2006; Liu et al., 2006). 
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1.2.2 Mesenchymal stem cells 
  Mesenchymal stem cells were firstly isolated from bone marrow and were cultured as adherent 
cells by Friedenstein et al (Friedenstein et al., 1966). In normal conditions, mesenchymal stem cells 
always reside in bone marrow and other tissues, such as adipose tissues, fetal skin, bone, umbilical 
cord blood (Bianco et al., 2008). But in pathological conditions such as inflammation and cancer, 
mesenchymal stem cells have been shown to be recruited to the lesion (Hung et al., 2005; Schichor 
et al., 2006). There are several literature describing mesenchymal stem cells can be recruited to 
tumor microenvironment as the result of tumor-secreted factors like SDF-1, VEGF, IL-8 in different 
tumor models like colon carcinoma, lung cancer, breast cancer, and so on (Birnbaum et al., 2007). 
When recruited into tumor microenvironment, these cells would take multi-faces roles in tumor 
formation and development (Birnbaum et al., 2007). For example, they may be involved in cancer 
stem cell niche formation and maintenance (Gilbertson and Rich, 2007), they can promote tumor 
vessel formation (Gilbertson and Rich, 2007) and suppress the immune system to help tumor cells to 
escape the killing of immunity (Bianchi et al., 2011; Klopp et al., 2011); they also can promote 
tumor invasion, migration and metastasis (Bianchi et al., 2011). In gliomas, there is no clear 
conclusion whether mesenchymal stem cells support or suppress the growth of tumor cells in 
different animal models. Adipose tissue derived mesenchymal stem cells can increase tumor size via 
inhibition of apoptosis in a U87 glioma model (Klopp et al., 2011). But on the other hand, umbilical 
cord blood derived mesenchymal stem cells can decrease tumor size via upregulation of PTEN in 
U251, SNB19 glioma models (Bianchi et al., 2011). Mesenchymal stem cells are not found in human 
brain until recently a population of mesenchymal stem-like cells are successfully isolated from brain 
tumor, and this population has been shown to promote the growth of glioma (Clavreul et al., 2012). 
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1.2.3 Endothelial cells 
  In general, the sprouting and proliferation of endothelial cells play an important role in tumor 
vasculature which supports the growing tumor mass with blood, nutrition and oxygen. In gliomas, 
the process of neovascularization is discussed as distinct phenomenon, angiogenesis and 
vasculogenesis (Jain et al., 2007). Angiogenesis, “the sprouting of new blood vessels via 
proliferation of pre-exsiting endothelial cells”, is supposed to play a major role in gliomas (Jain et al., 
2007). Vasculogenesis, “increasing recruitment of circulating endothelial progenitor cells or bone 
marrow derived hematopoietic cells”, also contribute to new vessel formation to support the 
progression of gliomas (Greenfield et al., 2010). Angiogenesis and vasculogenesis are two parallel 
processes in glioma tumorigenesis (Jain et al., 2007). Except them, recent research show CD133+ 
GBM stem-like cells can differentiate into endothelial progenitor cells (Wang et al., 2010). 
Glioma-isolated endothelial cells show similar typical endothelial markers, such as vWF, CD105, 
CD31, VE-cadherin, as endothelial cells in normal tissues (Charalambous et al., 2006). However, in 
contrast to endothelial cells in normal tissues, glioma-derived endothelial cells have larger, flat 
morphology and express high intercellular adhesion molecules (Charalambous et al., 2006). 
Moreover, glioma-derived endothelial cells show higher ability of cytotoxic resistance, migration 
and proliferation, and can produce higher mounts of growth factors like VEGF, IL-8 (Charalambous 
et al., 2006). Like endothelial cells in non-glial tumor (Garcia-Barros et al., 2003), glioma-derived 
endothelial cell not only contribute to the vessel formation but also regulate the therapy responses 
(Jain et al., 2007).  
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1.2.4 Hypoxia in gliomas 
  As conflict between demand of a fast growing tumor mass and support of relatively slow 
neovascularization, regional hypoxia play an important role in malignancy and becomes “a negative 
prognostic and predictive factor of tumor progression” (Wilson and Hay, 2011). In gliomas, the 
characteristic necrosis areas are considered to be hypoxia regions, which are frequent in malignant 
GBM (Jensen, 2009). In glioma cells, hypoxia may regulate gene alterations, invasion, migration, 
responses of radiotherapy and chemotherapy (Jensen, 2009). Clinical data show that hypoxia is 
correlated with therapy-resistance and predicts worse clinical outcome in patients with GBM (Flynn 
et al., 2008; Jensen, 2009). Hypoxia can regulate the expression of several molecules such as 
hypoxia inducible factor-1alpha (HIF-1α), Glucose transporter-1 (Glut-1), carbonic anhydrase 9 (CA 
IX) in gliomas (Flynn et al., 2008). These hypoxia-regulated proteins have grade-dependent 
expression in gliomas and increased expression of these molecules correlated with worse survival 
(Flynn et al., 2008). Moreover, hypoxia-regulated molecules are involved in several processes during 
tumor development, for example, HIF-1α can regulate the expression of genes that mediate adaptive 
responses (Jensen, 2009; Semenza, 2011). Expression of Glut-1 is not only linked to microvascular 
density and cell proliferation, but also limited to peri-necrotic regions in gliomas (Airley et al., 2010; 
Flynn et al., 2008). 
 
1.2.5 Cross-talk in tumor microenvironment of gliomas 
In general, a signaling interaction between various cell types in tumor microenvironment is critical 
importance of tumor formation, development and progression (Hanahan and Weinberg, 2011). The 
cross-talk is mediated through soluble factors and cell-cell contacts (Charles et al., 2011; Hanahan 
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and Weinberg, 2011). In gliomas, tumor cells can activate and educate the surrounding resident 
stromal cells to facilitate the tumor progression (Charles et al., 2011; Clavreul et al., 2012), they also 
can recruit stem/progenitor cells from host tissues by tumor-derived factors into tumor 
microenvironment, such as bone marrow derived mesenchymal stem cells (Hung et al., 2005; 
Schichor et al., 2006) . Stromal cells can secrete several factors including cytokines, growth factors, 
chemokines, then promote the initiation, invasion, proliferation of tumors (Parsons et al., 2008). 
Stromal cells also recruit immune cells to constitute an immunosuppressive environment to promote 
the tumor progression (Bianchi et al., 2011). Glioma stem cells have been shown to recruit 
endothelial cells into glioma stem cell niche, and these endothelial cells and other glioma cells are 
supposed to contribute to maintenance of the self-renewal ability of glioma stem cells (Gilbertson 
and Rich, 2007). 
 
1.3 Heat shock protein 70 
 
 Heat shock proteins (Hsps) are members of intracellular proteins, which mainly function as 
molecular chaperones to assist protein folding and translocation under stress conditions (Asea, 2006; 
Wallin et al., 2002). Heat shock proteins can be divided into different families according to their 
molecular weights, including Hsp10, Hsp27, Hsp40, Hsp60, Hsp70, Hsp90 and Hsp110. Heat shock 
protein 70(Hsp70) is the major stress-inducible heat shock protein with molecular weights of  70 
kDa (Calderwood et al., 2005). Hsp70 can be expressed in intracellular location and on the plasma 
membrane of several tumor cells, Hsp70 can also be secreted into extracellular space in the form of 
exosomes by tumor cells (Gehrmann et al., 2008b), as shown in Fig. 1-1.  
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Intracellular Hsp70 possesses a C-terminal domain, unfolding proteins and peptides, and a 
N-terminal ATPase domain which controls the peptide binding (Calderwood et al., 2005). Following 
stress, intracellular Hsp70, which is constitutively expressed in many tumor cell lines and tumor 
biopsies, fulfills protective functions and thus prevents lethal damage (Yaglom et al., 2007). In tumor 
cells, intracellular Hsp70 also participates in multi-steps in tumorigenesis, including the formation of 
a malignant phenotype, inhibition of programmed cell death, angiogenesis, invasion and metastasis 
(Calderwood et al., 2006). For example, high levels of intracellular Hsp70 might suppress 
senescence in colon carcinoma, breast cancer, prostate carcinoma cells, whereas depletion of 
intracellular Hsp70 has been shown to induce senescence via activation of TP53 pathway in colon 
and prostate carcinoma cell lines(Yaglom et al., 2007). In different types of cancer, strong 
intracellular Hsp70 expression is assumed to contribute to worsened clinical prognosis (Ciocca and 
Calderwood, 2005; Gehrmann et al., 2008b; Yaglom et al., 2007). For example, prostate carcinoma 
cells with high expression of intracellular Hsp70 are more resistant to chemotherapy (Roigas et al., 
1998). Intracellular Hsp70, which expressed in bladder urothelial carcinoma cell lines and clinical 
specimens, is associated with tumor progression such as migration and invasion (Garg et al., 2010) 
  
Extracellular Hsp70 which is secreted by necrotic tumor cells binds to adjacent cells or enters into 
bloodstream to distant sites (Calderwood et al., 2007). In viable tumor cells, the mechanisms for the 
secretion of extracellular Hsp70 are complex and incompletely understood (Mambula et al., 2007), 
but extracellular Hsp70 secretion can be enhanced following exogenous stress, such as 
pro-inflammatory cytokines (Barreto et al., 2003). For example, interferon-gamma has been shown 
to induce secretion of extracellular Hsp70 in breast adenocarcinoma cells and erythroleukemic cells 
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(Barreto et al., 2003; Bausero et al., 2005). Extracellular Hsp70 functions as an inducer of signal 
transduction cascades and transport of cargo molecules. On the other side, it acts as a danger signal 
and elicits immune responses (Calderwood et al., 2005; Multhoff, 2007). For example, extracellular 
Hsp70 from human liver carcinoma cell line HepG2 activate macrophage, dendritic cells and natural 
killer cells by a receptor-mediated pathway (Vega et al., 2008).  
 
In non-glial tumors, membrane Hsp70 expression has been described uniquely on the surface of 
tumor cells, but not in the surrounding non-neoplastic tissues or normal cells. The externalization of 
intracellular Hsp70 to the membrane-associated form under stress conditions serving as a 
“danger-signal” is investigated (Hightower and Guidon, 1989; Vega et al., 2008). Multhoff et al 
show the minimal membrane Hsp70 sequence is just a 14-mer Hsp70 peptide 
(TKDNNLLGRFELSG) termed TKD, thus a special antibody cmHsp70.1 targeting membrane 
Hsp70 is generated by using TKD as immunogen  (Multhoff and Hightower, 2011). Both on viable 
human and mouse tumor cells and in tumor-bearing mice, the cmHsp70.1 antibody is used to 
selectively detect the C-terminal substrate binding domain (Multhoff and Hightower, 2011; Radons 
and Multhoff, 2005; Stangl et al., 2011b). Membrane Hsp70 expression was shown to be regulated 
by anti-inflammatory drugs and antineoplastic agents (Calderwood et al., 2005; Gehrmann et al., 
2004; Multhoff, 2007; Pfister et al., 2007). For instance, in a leukemic cell line and colon carcinoma 
cell line, compared to DNA-interacting antitumor agents (cytarabine, ifosfamid), vincristine and 
paclitaxel can increase not only the cytoplasmic but also the membrane Hsp70 expression 
(Gehrmann et al., 2002). Membrane Hsp70 is correlated with different clinical outcomes in different 
cancers. For example, the membrane Hsp70-positive phenotype has been associated with a higher 
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metastatic potential and an unfavourable prognosis in malignant melanoma, acute myeloid 
leukaemia as well as lower rectal and squamous cell carcinoma of the lung (Farkas et al., 2003; 
Pfister et al., 2007). However, in colon and gastric cancer, membrane Hsp70 expression correlates 
with a significantly improved survival (Pfister et al., 2007).  
 
Membrane Hsp70 exosomes, which can associate with lipid raft sphingolipid 
globoyltriaosylceramide Gb3 and phosphatidylceramide components in membrane of tumor cells, 
can be released from membrane Hsp70 positive tumor cells (Multhoff and Hightower, 2011). The 
secretion of membrane Hsp70 was described to be in an ATP binding cassette-dependent 
lysosomal/endosomal pathway (Mambula et al., 2007; Multhoff and Hightower, 2011). The secretion 
is induced by neither high/low concentration of salt nor PH change (Vega et al., 2008). Membrane 
Hsp70 exosomes can induce the migratory and cytolytic activity of natural killer cells to initiate 
apoptosis in tumor cells (Elsner et al., 2007; Multhoff, 2007; Radons and Multhoff, 2005). 
Membrane Hsp70 exosomes have been shown to induce the accumulation and activation of 
suppressive immune cells to help tumor cells escape from immunity killing in human and mouse 
(Chalmin et al., 2010). So clear functions of membrane Hsp70 is still unknown. 
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   Fig 1-1: The distribution of different forms of Hsp70 in cells: intracellular Hsp70, extracellular Hsp70, 
membrane Hsp70 and membrane Hsp70 exosomes. Intracellular Hsp70 can be found in cytoplasm and nucleus 
of tumor cells and apoptotic cells, extracellular Hsp70 can be secreted from apoptotic cells, membrane Hsp70 can 
be expressed on the surface of tumor cells and be secreted by tumor cells in form of exosomes. 
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1.4 Aims of this study 
 
Several studies investigated the expression of intracellular Hsp70 in GBM cell lines and in tumor 
specimens from GBM patients (Hermisson et al., 2000), but not the membrane Hsp70 (Elsner et al., 
2007; Hermisson et al., 2000). But there was no direct correlation between intracellular Hsp70 
expression and radioresistance of glioma cell lines (Fedrigo et al., 2011) or clinical outcome of 
patients with GBMs (Hermisson et al., 2000). Thus, the expression of membrane Hsp70 in gliomas 
was investigated in the current study.  
The aims of this study: 
1.  To investigate the expression of the specific membrane Hsp70 in gliomas regarding 
grade-dependency and to compare its expression in primary GBM and secondary GBM. 
2.  To detect the localization of membrane Hsp70 within GBM tissues and to investigate a potential 
co-expression with hypoxic markers.  
3.  To define the membrane Hsp70-positive subpopulations isolated from primary GBM. 
4.  To determine whether hypoxia can induce membrane Hsp70 expression in GBM-derived 
subpopulations. 
5.  To investigate secretion of membrane Hsp70 into conditioned media of different isolated 
populations and to compare the secretion of membrane Hsp70 in serum of patients with primary 
and secondary GBM. 
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2 Materials and methods 
 
2.1 Tissue samples 
 
  Tumor probes for cell isolation and tissue specimens were acquired directly from patients with 
gliomas (n = 65), non-neoplastic brain were aquired from temporal lobe resections of epilepsy 
patients in Department of Neurosurgery, University of Munich. The study was approved by the local 
ethical committee, written informed consent was obtained from all patients. Diagnosis was made by 
the Dept. of Neuropathology, University of Munich, according to WHO criteria. N= 55 tissue 
samples (non-neoplastic brain n = 3, astrocytoma WHO II n = 5, astrocytoma WHO III n = 11, 
primary GBM n = 23, secondary GBM n = 13) were investigated for immunohistochemistry and 
n=10 samples were investigated for isolation of cell subpopulations. 
 
2.2 Immunohistochemistry 
 
Tumor tissues were obtained from tumor resections of glioma patients and non-neoplastic brain 
samples were obtained from temporal lobe resections of epilepsy patients. Fresh tissues were fixed 
according the manufacturer’s protocol of HOPE (Hepes-glutamic acid buffer-mediated organic 
solvent protection effect) formula (Wiedorn et al., 2002) and embedded in paraffine. All 
immunohistochemical stainings of non-neoplastic and gliomas tissues were performed in the 
tumorbiology laboratory, Department of Neurosurgery by using DAB staining kit. In brief, 
HOPE-treated, paraffin-embedded tissue sections were deparaffined and unmasked the epitope by 
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treating the sections in 100% isopropanol at 60 ºC for 30 min, then fix in 70% ice-cold acetone at 
-20 ºC for 10 min, washed in water for 10min, the slides were then incubated with peroxidase 
blocking buffer at room temperature for 10 min for peroxidase blocking. After a washing step in 
phosphate-buffered saline for two times, the slides were incubated with protein blocking buffer at 
room temperature for 30 min for nonspecific binding blocking. Then the slides were incubated 
overnight at 4 ºC with the primary antibodies shown in Table 2-1. Following three 10-min washing 
step in TBS, the slides were incubated with the anti-mouse biotinylated antibody at room 
temperature for 15 min. After 5-min washing in TBS, the slides were incubated with horse radish 
peroxidase at room temperature for 20 min. After three 10-min washings in TBS, the expression was 
detected by using DAB Chromogen and nuclei were counterstained with haematoxylin. After 
dehydration with methanol for 30 min, the slides were coverslipped with entellan and 
microscopically photographed for further analysis. 
 
Table 2-1: Antibodies list for immunohistochemistry. 
Antibody Company  Cat.No Quantity Dilution 
IDH1 Dianova,Germany DIAH09 0.2mg/ml  1:50 
cmHsp70.1 Multimmune,Germany  2.4mg/ml  1:50  
cytoHsp70 Enzo life Sciences, Switzerland ADI-SPA-810 1.0mg/ml  1:50 
Glut-1 Dako,Germany A3536 2.2mg/ml  1:100 
HIF-1alpha Santa Cruz,USA sc-53546 0.2mg/ml  1:50 
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2.3 Isolation and cultivation of Cell samples 
 
2.3.1 Isolation of primary GBM cell culture 
All tumor tissues used for cell isolation were obtained from patients with primary GBM. Tumor 
tissues were kept on ice immediately after resection and processed to cell isolation in 2 hours. In 
brief, tumor tissue was minced into small pieces and then homogenized in Dulbecco’s MEM 
medium supplemented with 20% fetal calf serum, antibiotics mix consisting of penicillin, 
streptomycin and glutamine as well as non-essential amino acids. After 60-min enzyme digestion at 
37 ºC and filtration with 70-μm filter, the single-cell suspension was obtained. To isolate 
glioblastoma primary culture, this suspension was directly cultured in DMEM supplemented with 
20% FCS medium.  
2.3.2 Isolation of CD133-positive cells 
To isolate CD133-positive cells, tumor tissue-derived single-cell suspension was separated using 
MACS-column according to manufacturer’s protocol with anti-CD133 antibody, the positive isolated 
cells were cultured with DMEM/ F12 supplemented with N2, B27, hEGF and FGF in 
Gelatine-coated plastic flasks. The expression of CD133 was determined by flow cytometry with 
two different phenotype CD133 antibodies (Miltenyi, Germany). 
2.3.3 Isolation of endothelial cells 
  To isolate CD-31-positive microvascular endothelial cells from GBM, tumor tissue-derived 
single-cell suspension was separated by using Dynabeads magnetic beads with anti-CD31 antibody. 
CD31 positive endothelial cells were plated in 2% gelatine coated plastic flasks and cultured with 
Microvascular Endothelial Cell Growth Medium (Provitro Company, Germany). 
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2.3.4 Isolation of mesenchymal stem-like cells 
To isolate GBM-derived mesenchymal stem cells, tumor tissue-derived single-cell suspension 
was used. After Ficoll-gradient sorting, the mononuclear cells were obtained and cultured in DMEM 
supplemented with 20%FCS. The glioblastoma-derived mesenchymal stem-like cells analyzed for 
mesenchymal stem-like cell markers by flowcytometry and the ability of osteogenic and adipogenic 
differentiation was determined in vitro. 
2.3.5 Normoxia and hypoxia cultivation 
GBM cell lines U87 and U373 were purchased from ATCC (Manassas, VA, USA) and cultured 
in Dulbecco’s MEM medium supplemented with 10% fetal calf serum, antibiotics mix and MEM 
non-essential amino acids. 
All cells were cultured in plastic flasks and kept in humidified atmosphere, 5% CO2 at 37º C. 
Trypsin/EDTA solution was used for passaging . Medium was changed every 48 hours. All cells 
were analyzed at passage 1-3. To treat cells with hypoxia incubation (0.01% O2, humidified 
atmosphere and 5% CO2 at 37 ºC in the hypoxia incubator) for 72h, cells were cultured in normal 
condition at first and change to fresh medium before hypoxia incubation. 
 
2.4 Characterization of cell samples 
 
2.4.1 Osteogenic and adipogenic differentiation of mesenchymal stem cells 
To detect the differentiation potential of isolated mesenchymal-like stem cells, osteogenic and 
adipogenic differentiation were performed as described previously(Hong et al., 2005; Kim et al., 
2003; Oswald et al., 2004). In brief, for osteogenic differentiation, 1x10
4
 cells were seeded in 
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12-well plates with DMEM medium for 3 days, then switched to differentiation medium which 
supplemented with 0.1µM Dexamethasone, 10mM beta-glycerophosphate, 0.05mM L-ascorbic acid, 
with medium changed every 3 days. After 14 days, plates were stained with Kossa staining and 
photographed. For adipogenic differentiation, 1x10
5
 cells were seeded in 12-well plate with normal 
DMEM medium for 3 days, then were switched to differentiation medium which supplemented with 
1µM dexamethasone, 0.5µm isobutylmethylxanthine, 100µm indomethacin, 10µg/ml insulin, with 
medium changed every 3 days. After 14 days, plates were stained with Oil Red O and photographed. 
2.4.2 Tube formation of endothelial cells 
To detect the ability for three dimensional cellular organization potential of isolated endothelial 
cells, tube formation assay on Ibidi angiogenesis slide (ibidi GmbH, Germany) was performed as 
described previously (Kumar et al., 2003). In brief, matrigel was plated on Ibidi angiogenesis slide 
after thrawing on ice, then was incubated at 37℃ for 30 min to allow matrigel to polymerize. 1x104 
endothelial cells with 50µl medium were seed into coated wells. After incubation for 24 hours at 
37℃ in 5% CO2 humidified atmosphere, the plates were photographed. 
  
2.5  Fluorescence activated cell sorting (FACS) 
 
Cultured cells were washed with PBS and detached from flask using Trypsin/ EDTA at 37 ºC for 
3min. For Hsp70-FACS analysis, after washing with FACS buffer (PBS supplemented with 10% 
FCS) membrane-Hsp70-specific mouse monoclonal IgG1 antibody cmHsp70.1-FITC and FITC 
conjugated IgG1 isotype-matched negative control immunoglobulin for 30min on ice in the dark. 
After another washing step, cells were resuspended in 500µl FACS buffer. 5µl propidium iodide for 
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viability staining was added. Only propidium iodide negative cells were analyzed on a FACS Calibur 
flow cytometer (BD Biosciences, USA). For CD133-FACS-analysis, PE-coupled-antibody from 
Miltenyi Biotechnology with the corresponding IgG control was used. The following markers shown 
in table 2-2 for endothelial cells and mesenchymal stem-like cells were tested: CD31, CD34, CD44, 
CD45, CD90 and CD105. Data analysis was performed with flowjo® 6.7.1 (Treestar, California, 
USA).  
 
2.6 Enzyme-linked immunosorbent assay (ELISA) 
 
Serum from patients with epilepsy and primary and secondary GBM and conditioned medium 
from isolated cell populations, including primary tumor cell culture, endothelial cells, and 
mesenchymal stem-like cells, were used to detect the concentration of membrane Hsp70 in exosome 
form. To obtain serum samples, blood samples were centrifuged for 10 min at 15,000 g to remove all 
debris. The patients list is shown in Table 3-3. To obtain conditioned medium from isolated cell 
subpopulations, 1x10
5
 cells were seeded into 24-well plates with 500ul medium supplemented 
without FCS or growth factors. After 48-hour incubation in humidified atmosphere at 37℃, 
conditioned medium was collected and centrifuged at 15,000 g to remove all debris, the list of 
conditioned medium is also shown in Table 3-2. All serum and conditioned medium samples were 
stored at -80℃ for tests.  
A sensitive sandwich enzyme-linked immunosorbent assay was performed by using Hsp70 Duo 
Set IC kit according to the protocol of the manufacturer. Briefly, samples and standards were added 
to a 96-well plate coated with a mouse anti-human Hsp70 capture antibody and incubated for 2h at 
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room temperature. After being washed, the plate was incubated with anti-Hsp70 detection antibody 
conjugated to horseradish peroxidase at room temperature. Color reaction was performed by using a 
substrate solution and stopped with an acid solution. Finally, absorbance was measured with a 
microplate reader at a wavelength of 450nm. A standard curve should be generated for samples 
assayed and calculated. 
 
2.7 Statistical analyses 
 
The ELISA data were summarized as the mean ± SEM (standard error of the mean). Statistical 
analysis was performed using student’s test (as indicated in the figure legend or the text). Statistical 
significance was accepted at the P<0.05 level. 
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Table.2-2: Antibodies list for FACS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody Company 
PE labelled-CD45 Serotec 
PE labelled-CD44 Serotec 
PE labelled-CD90 Serotec 
PE labelled-CD105 Serotec 
PE labelled-CD34 BD 
PE labelled-CD29 Serotec 
PE labelled-CD31 Serotec 
PE labelled-CD133/1 miltenyi 
PE labelled-CD133/2 miltenyi 
FITC labelled-cmHsp70 multimmune 
PE labelled- IgG1 Serotec 
PE labelled-IgG2a Serotec 
PE labelled-IgG1 MACS 
PE labelled-IgG1 BD 
FITC labelled-IgG1 BD 
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3 Results 
 
3.1 Membrane Hsp70 is over-expressed in (primary) GBM tissues, but not in normal brain and 
WHO grade II and III gliomas 
 
  To investigate the expression of membrane Hsp70 in gliomas, immunohistochemistry staining of 
membrane Hsp70 in primary GBM (n=23), non-neoplastic brain (n=3), diffuse astrocytoma (n=5) 
and anaplastic astrocytoma (n=11) was studied, as shown in Table. 3-1. In non-neoplastic brain, no 
positive expression of membrane Hsp70 could be detected. In WHO grade II and III gliomas, there 
was also no positive signal for membrane Hsp70 (Fig. 3-1). Compared to normal brain and WHO 
grade II and III gliomas, all primary GBM tissues (n=23) showed strong positive expression of 
membrane Hsp70. In primary GBMs, the membrane Hsp70 positive expression always localized 
within tumor parenchyma, and strongest expression was found in peri-necrotic regions. There was 
no positive signal for membrane bound Hsp70 in tumor vessels neither in normal brain nor in 
gliomas of different grades.   
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Fig.3-1: Expression of membrane Hsp70 and corresponding negative control in non-neoplastic brain 
(No.TB409), diffuse astrocytoma (WHO grade II, No.TB400), anaplastic astrocytoma (WHO grade III, 
No.TB665) and primary GBM (WHO grade IV, No.TB771). In normal brain (A2) and WHO grade II (B2) and 
III (C2) astrocytomas, there was no detectable expression of membrane Hsp70. Only in primary GBM (D2), strong 
brown signals could be detected within the tumor and were supposed to be specific positive membrane Hsp70 
expression. Magnification x20. 
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3.2 Expression of intracellular Hsp70 and membrane Hsp70 in normal brain and WHO grade 
II or III astrocytomas 
 
  Heat shock protein 70 was previously described in the intracellular localization of tumor cells, but 
was not only found on the membrane of tumor cells (Calderwood et al., 2005). To compare the 
expression of intracellular Hsp70 and membrane Hsp70 in normal brain and gliomas (including 
diffuse astrocytoma and anaplastic astrocytoma), different antibodies which separately aim to the 
membrane or intracellular localized antigens of Hsp70 were used for immunohistochemistry. In our 
immunohistochemical staining, intracellular Hsp70 could be found in a few cells within normal 
brain and grade II and III glioma tissues and also vessel-associated cells (Fig.3-2; Table.3-1). The 
expression of intracellular Hsp70 did not show any correlation to the tumor grade, we found positive 
signals in most of diffuse astrocytomas and anaplastic astrocytomas (Fig.3-2; Table.3-1), which is in 
line with previous publications (Hermisson et al., 2000). In comparison with the results of 
intracellular Hsp70, there was no positive signal for membrane Hsp70 in non-neoplastic brain or 
WHO grade II or III glioma tissues. In line with the histopathological diagnosis obtained by the 
neuropathological department, we found positive signal for IDH-1 mutation which was uniquely 
expressed in the parenchyma of WHO grade II (5 positive samples of 5 samples) and III gliomas (8 
positive samples of 11 samples). WHO grade II and III gliomas expressed mutated IDH-1 in a 
variety of cells within the tumor, whereas no positive signal was detectable in normal brain (Fig.3-2; 
Table.3-1). 
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Fig.3-2: Immunohistochemical staining of intracellular Hsp70 (A1, B1, C1), membrane Hsp70 (A2, B2, C2), 
mutated IDH-1 (A3, B3, C3) and corresponding negative control (A4, B4, C4) in normal brain (No.TB409), 
diffuse astrocytoma (WHO grade II, No.TB400), anaplastic astrocytoma (WHO grade III, No.TB579). 
Expression of intracellular Hsp70 was not grade-dependent. It could be positive or negative in normal brain (A1) 
and WHO grade II (A2) and III (A3) astrocytomas. Compared with intracellular Hsp70, membrane Hsp70 showed 
definite negative expression in normal brain (A2) and WHO grade II (B2) and III (C2) astrocytomas. Expression of 
Mutated IDH-1 could be found both in WHO grade II (B3) and III (C3) astrocytomas, but not in normal brain (A3). 
(Magnification: X20, X40). 
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3.3 Expression of membrane Hsp70 is detectable in primary GBM but not secondary GBM 
 
To compare the membrane Hsp70 expression in primary GBMs and secondary GBMs, 23 primary 
GBMs and 13 secondary GBMs were immunohistochemical stained. In all primary GBMs (N=23; 
table.3-1), we detected clear upregulation of membrane Hsp70 expression compared to the low grade 
tumors (Fig. 3-1). Interestingly, secondary GBMs tissue did not show any positive signal for 
membrane Hsp70 (n = 13; Fig. 3-3; Table 3-1). In line with previous studies (Watanabe et al., 2009; 
Yan et al., 2009) and the histopathological diagnosis obtained by the neuropathological department, 
mutated IDH-1 staining was performed in every sample as a marker for secondary GBM, ten of 
thirteen samples of 13 were positive. Selectively tumor cells expressed mutated IDH-1 in secondary 
GBM tissues (10 positive samples of 13 samples). As expected, none of the primary GBM tissues 
expressed mutated IDH-1 (n = 23).  
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Fig.3-3: Immunohistochemical stainings of membrane Hsp70 (A1, B1), mutaed IDH-1 (A2, B2) and 
corresponding negative control (A3, B3) in primary GBM (No.TB410) and secondary GBM (No.TB490). 
Membrane Hsp70 was clearly upregulated in primary GBM (A1) within tumor tissue but not in gliomeruloid vessel 
proliferation area. But there was no expression in secondary GBM (B1). Mutated IDH-1 was expressed uniquely in 
secondary GBM (B2) but not in primary GBM (A2), as already described in literatures. (Magnification: X20, X40) 
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3.4 Membrane Hsp70 is expressed in GBM cells lines, primary tumor cell cultures, and 
CD133-positive cells, but not in mesenchymal stem-like cells, endothelial cells and 
bone-marrow derived stem cells 
 
To further investigate the expression of membrane Hsp70 in the tumor microenvironment of 
primary GBM, different subpopulations (including primary tumor cell cultures, CD133 positive cells, 
mesenchymal stem-like cells, endothelial cells) were isolated from resected tumor specimens in 
primary GBM patients and checked for membrane Hsp70 expression by FACS. GBM cell lines U87 
and U373 and Bone marrow derived mesenchymal stem cells, as negative control for GBM derived 
mesenchymal stem-like cells, were also determined. 
 
3.4.1 Membrane Hsp70 expression in GBM cell lines and primary tumor cell cultures 
GBM cell lines U87 and U373 were analysed for membrane Hsp70 expression. The GBM cell 
line U87 and U373 showed strong positive signal for FITC-conjugated membrane Hsp70 with mean 
fluorescent intensities of 35 – 65 (data not shown). Primary tumor cell cultures, isolated from 
primary GBM also showed positive signals for FITC-conjugated-membrane Hsp70 in general, but in 
different extents regarding the mean fluorescent intensity (Fig3-7.A). 
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3.4.2 Membrane Hsp70 expression in CD133 positive cells 
CD133 positive cells, which were isolated from GBM patients and culture with growth factors, 
grown in plastic-adherent morphology on coated flask and stably expressed CD133 markers 
(Fig.3-4). The expression of membrane Hsp70 on CD133-positive cells was positive. Compared with 
GBM-isolated primary tumor cell cultures, CD133 positive cells showed weaker positive expression 
of membrane Hsp70 (Fig.3-7.B). 
 
              
 
Fig.3-4: Characterization of CD133 positive cells. (A) Cells were isolated by using MACS-column and 
cultivated in Gletine-coated flask with DMEM/F12 medium supplemented with growth factors, after 15 days, cells 
growth as adherent morphology. (B) Cells were still CD133 positive after cultivation for several passages in vitro, 
the expression were determined by FACS. 
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3.4.3 Membrane Hsp70 expression in GBM derived endothelial cells 
In general, endothelial cells always show CD31 and VEGFR-2 positive expression, which were 
shown by immunohistochemisty staining of tumor tissues and FACS (Fig.3-5). Moreover, the tube 
formation assay of endothelial cells which isolated from GBM was performed on matrigel to 
confirm its vessel formation capability, as shown in Fig 3-5. No expression of membrane Hsp70 on 
GBM derived endothelial cells was shown (Fig .3-7.C). 
 
 
Fig.3-5: Characterization of endothelial cells. Endothelial cells in GBM tissues expressed CD31 (A) and 
VEGFR-2 (B). After several passages cultivation in vitro, endothelial cells derived from GBM showed similar 
morphology (C) and tube formation ability in matrigel assay (D). 
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3.4.4 Membrane Hsp70 expression in GBM derived and bone marrow derived mesenchymal 
stem-like cells 
 
Mesenchymal stem cells were defined as plastic-adherent cells under standard culture condition; 
in standard culture conditions, cells have positive expression of CD105, CD90, CD44, and negative 
expression of CD14, CD34, CD45; In vitro, mesenchymal stem cells can differentiate into osteocytes, 
adipocytes, and chondrocytes under specific stimuli (Horwitz et al., 2005). As shown in Fig.3-6, this 
subpopulation isolated from primary GBM was identified to be mesenchymal stem-like cells. The 
expression of membrane Hsp70 in mesenchymal stem-like cells isolated from GBM tissue was 
negative, as shown in Fig.3-7.D, and was similar with the expression in mesenchymal stem cells 
isolated from bone marrow (Fig.3-7.E).  
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Fig.3-6: Characterization of GBM derived mesenchymal stem-like cells. (A) Isolated mesenchymal stem-like 
cells were plastic-adherent in DMEM medium supplemented with 20% FCS. (B) In adipogenic differentiation 
assay, isolated mesenchymal stem-like cells were cultured in differentiation medium for 14 days, and stained 
following kossa staining (upper) and Oil red S (lower). (C) Isolated mesenchymal stem-like cells were checked for 
typical markers by FACS analysis. Comparing with FITC labelled IgG (blue line), FITC labelled CD31, CD34, 
CD45 (red line) were negative and CD44, CD90, CD105 (red line) were positive. 
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Fig.3-7: Expression of membrane Hsp70 in isolated subpopulations. Among these subpopulations, the 
expression in primary tumor cell culture (A) was strong positive, the expression in CD133 positive cells (B) was  
positive but was not as strong as primary tumor cell culture. On the other hand, the expression in endothelial cells 
(C), mesenchymal stem-like cells derived from GBM tissue (D) and bone marrow (E) was negative. The 
expression was analyzed by FACS. 
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3.5 Hypoxia increases the expression of membrane Hsp70 in GBM cell lines and primary 
tumor cell cultures. 
 
Hypoxia, which contributes to invasion, necorsis, therapy-resistance, recurrence, is a major feature 
in GBM (Oliver et al., 2009). Herein, the effect of hypoxia on the expression of membrane Hsp70 in 
primary GBM was investigated. After cultivation of GBM cell lines U87 under normoxia and 
hypoxia (0.01% O2 saturation) for 72h, cells were analyzed for FITC-conjugated-membrane Hsp70 
expression. Compared to the normoxic group, mean fluorescent intensity was doubled in the hypoxic 
group (Fig 3-8A).  
For primary tumo cell culture from GBM, the induction of FITC-conjugated- membrane Hsp70 
expression phenomenon could also be achieved (Fig.3-8B). In the other subpopulations including 
GBM derived mesenchymal stem-like cells ((Fig.3-9A), endothelial cells (Fig.3-9B) and bone 
marrow-derived stem cells (Fig.3-9C), which did not show any membrane Hsp70 expression under 
normoxia, membrane Hsp70 expression could not be induced under hypoxia cultivation. Thus, 
hypoxia can only increase the expression of membrane Hsp70 in positive cell subpopulations, but 
not in membrane Hsp70 negative cell subpopulations. 
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Fig.3-8: Hypoxia incubation effect on membrane Hsp70 expression in GBM tumor cell line U87 (A) and 
GBM derived primary tumor cell cultures (B). U87 and primary tumor cell culture was positive for membrane 
Hsp70. After 72-hour cultivation in hypoxia, the expression increased. The expression was analyzed by FACS.  
 
Fig.3-9: Hypoxia incubation has no effect on membrane Hsp70 expression on membrane Hsp70 negative 
expression isolated subpopulations. GBM derived endothelial cells (B) and mesenchymal stem-like cells (A) 
showed negative membrane Hsp70 expression and the expression did not increase after hypoxia cultivation. Bone 
marrow derived mesenchymal stem-like cells (C) showed similar result under hypoxia cultivation. The expression 
was analyzed by FACS. 
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3.6 Expression of membrane Hsp70 in GBM tissue regarding localization to hypoxic areas 
 
To detect hypoxia regions in gliomas of different grades, hypoxia marker Glut-1 was investigated. In 
normal brain and WHO grade II and III gliomas, Glut-1 was shown to be expressed in the 
erythrocytes and endothelial cells but not in the tumor parenchyma, shown in Fig.3-10. These results 
were in line with already pulished studies (Rademakers et al., 2011; Vaupel and Mayer, 2007). To 
further investigate the relationship between hypoxia and the expression of membrane Hsp70 in 
primary GBM tissues, expression of hypoxia markers (Glut-1 and HIF-1alpha) and membrane 
Hsp70 on primary GBM tissue were analyzed by immunohistochemistry. In Glut-1 staining of 
consecutive slides in primary GBM tissue (n = 23), a coexpression of membrane Hsp70 (Fig. 3-11, 
D1) and Glut-1 (Fig. 3-11, B1) was detected in perinecrotic areas and weaker in non-hypoxic tumour 
parenchyma. In vascularized areas, no membrane Hsp70 or Glut-1 expression could be found on 
endothelial cells and the surrounding tumour tissue (Fig. 3-11, D2 and B2). HIF-1α, another marker 
for hypoxia, showed similar localization for positive signal compared to Glut-1 (Fig. 3-11, C1). But 
HIF-1α was expressed much weaker than Glut-1 and positive signal for HIF-1α could also be found 
in well vascularized areas within the tumor tissue (Fig. 3-11, C2). 
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Fig.3-10: Immunohistochemical stainings of hypoxia marker Glut-1 (upper line) as well as corresponding 
negative control (lower line) was performed in non-neoplastic brain, WHO grade II and III gliomas. In 
normal brain and WHO grade II and III gliomas, Glut-1 was shown to be expressed in the erythrocytes and 
endothelial cells but not in the tumor parenchyma. 
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Fig. 3-11: Immunohistochemical stainings of hypoxia markers Glut-1 and HIF-1α as well as membrane 
Hsp70 were performed in consecutive slides of primary GBM. Positive statining of Glut-1 and HIF-1α was 
localized in peri-necrotic areas of the tissue (B1, C1, D1). Also membrane Hsp70 expression could be found in 
peri-necrotic zone. In good vascularized tumour areas around a big vessel (B2) no Glut-1 expression was detected 
whereas HIF-1α expression was present (C2). Membrane Hsp70 showed colocalization with Glut-1 signal and 
could not be detected in vital tumour areas in vascularized areas (D2). 
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3.7 Membrane Hsp70 is highly secreted by primary tumor cell cultures, but not by 
endothelial cells and mesenchymal stem-like cells 
 
As membrane Hsp70 on tumor cells could be secreted into the blood stream as a form of 
exosomes (Calderwood et al., 2005; Multhoff and Hightower, 2011). To investigate the secretion of 
membrane Hsp70 in different subpopulations, conditioned media were investigated via ELISA 
(Fig.3-12, Table.3-2). Only conditioned media from primary tumor cell cultures (n=4) showed high 
concentration of membrane Hsp70 protein, but much lower levels in conditioned media from 
endothelial cells (n=3) or mesenchymal stem-like cells (n=3). Three of four primary tumor cell 
cultures secreted more than 2000 pg/ml membrane Hsp70 into conditioned media (1803 pg/ml to 
9834pg/ml, mean 5754pg/ml), endothelial cells (699pg/ml to 1885pg/ml, mean 1203pg/ml) and 
mesenchymal stem-like cells (883pg/ml to 2028pg/ml, mean 1544pg/ml) secreted significantly lower 
levels of membrane Hsp70 into conditioned media. 
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Fig.3-12: Determination of membrane Hsp70 in the conditioned mediums of primary GBM-derived 
subpopulations, including primary tumor cell cultures, endothelial cells, mesenchymal stem cells. Detail in 
Table.3-2. Membrane Hsp70 expression was analyzed by ELISA. Membrane Hsp70 concentration in three of four 
conditioned media of primary tumor cell cultures was >2000 pg/ml. But the values in the conditioned media of 
endothelial cells, mesenchymal stem-like cells were in a lower range, which were considered as basic levels. 
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3.8 Membrane Hsp70 is increased in serum of patients with primary GBM but not secondary 
GBM 
 
In order to further validate the membrane Hsp70 secretion in vivo in primary GBM and 
secondary GBM, the concentration of membrane Hsp70 in serum samples was determined by using 
ELISA. As shown in Fig.3-13, compared with secondary GBM (8254±2277pg/ml) and normal 
control (9782±2646pg/ml), primary GBM (19009±1614pg/ml) showed significant higher membrane 
Hsp70 expression (p<0.01) in serum. So in the line with immunohistochemical staining results, 
primary GBM patients had higher levels of secreted membrane bound Hsp70 in the serum than 
secondary GBM patients.  
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Fig.3-13: Membrane Hsp70 expression in serum of normal brain, primary GBM and secondary GBM. 
Serum were obtained from blood of 5 normal brain, 16 primary GBM and 9 secondary GBM patients, membrane 
Hsp70 concentration was determined by ELISA kits. The result showed concentration of secreted membrane 
Hsp70 was much higher in serum of patients with primary GBM than patients with secondary GBM (P<0.01) and 
control (P<0.05).   
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Table. 3-1: Overview of immunohistochemistry tissue 
 
    antibody       
Number IDH1 Glut-1 mHsp70 iHsp70 pathology  
TB409 negative positive negative positive normal brain 
TB547 negative positive negative  normal brain 
TB601 negative positive negative  normal brain 
      
TB400 positive positive negative positive astrocytoma II 
TB411 positive positive negative  astrocytoma II 
TB425 positive positive negative  astrocytoma II 
TB509 positive positive negative  astrocytoma II 
TB729 positive positive negative  astrocytoma II 
      
TB538 positive positive negative  astrocytoma III 
TB560 positive positive negative negative astrocytoma III 
TB578 negative (previous grade II) positive negative  astrocytoma III 
TB579 positive positive negative negative astrocytoma III 
TB625 negative (previous grade II) positive negative  astrocytoma III 
TB637 positive positive negative   astrocytoma III 
TB665 positive positive negative positive astrocytoma III 
TB672 positive positive negative  astrocytoma III 
TB707 negative positive negative  astrocytoma III 
TB750 positive (PCR) positive negative  astrocytoma III 
TB781 positive positive negative positive astrocytoma III 
      
TB402 negative positive positive  primary GBM 
TB410 negative positive positive positive primary GBM 
TB426 negative positive positive   primary GBM 
TB500 negative positive positive  primary GBM 
TB503 negative positive positive  primary GBM 
TB541 negative positive positive negative primary GBM 
TB650 negative positive 
weakly 
positive negative primary GBM 
TB697 negative positive positive  primary GBM 
TB704 negative positive positive  primary GBM 
TB771 negative positive positive positive primary GBM 
TB773 negative positive positive  primary GBM 
TB792 negative positive positive positive primary GBM 
TB804 negative positive positive positive primary GBM 
TB817 negative positive positive  primary GBM 
TB824 negative positive positive  primary GBM 
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TB833 negative positive positive  primary GBM 
TB834 negative positive positive  primary GBM 
TB837 negative positive positive  primary GBM 
TB853 negative positive positive  primary GBM 
TB869 negative positive positive  primary GBM 
TB875 negative positive positive  primary GBM 
TB877 negative positive positive  primary GBM 
TB878 negative positive positive  primary GBM 
      
TB348 positive positive negative positive secondary GBM 
TB490 positive positive negative positive secondary GBM 
TB551 positive positive negative positive secondary GBM 
TB558 
negative (previous grade 
III) positive negative negative secondary GBM 
TB607 positive positive negative negative secondary GBM 
TB715 
negative (previous grade 
III) positive negative negative secondary GBM 
TB716 positive positive negative   secondary GBM 
TB742 positive positive negative  secondary GBM 
TB747 positive positive negative  secondary GBM 
TB785 
negative (previous grade 
III) positive negative  secondary GBM 
TB819 positive positive negative  secondary GBM 
TB857 positive positive negative  secondary GBM 
TB858 positive positive negative   secondary GBM 
 
Table 3-1: This table is an overview of all stained tissue regarding the following markers: IDH-1, Glut-1, 
intracellular Hsp70 (iHsp70) and membrane Hsp70 (mHsp70). In WHO grade II and III gliomas, mutated 
IDH-1 expression was positive, Glut-1 and intracellular Hsp70 expression was variable positive, but membrane 
Hsp70 expression was negative. In primary GBM, mutated IDH-1 expression was negative whereas membrane 
Hsp70 expression was always positive. Intracellular Hsp70 expression was variable and Glut-1 expression could be 
deteced in vessels and necrotic areas. In secondary GBM, mutated IDH-1 expression (in immunohistochemistry of 
PCR) was positive whereas membrane Hsp70 expression was totally negative. Glut-1 expression could be found 
mainly in vessels and intracellular Hsp70 expression was variable. 
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Table.3-2: ELISA results of secreted membrane Hsp70 in conditioned media. 
   
 
 
 
       
 
 
 
 
 
 
 
 
Table3-2: This table showed ELISA results of secreted membrane Hsp70 in conditioned media of 
subpopulations isolated from primary GBM: primary tumor cell cultures (PK, n=4), endothelial cells (EC, 
n=3) and mesenchymal stem-like cells (MSC, n=3). Values were extremely low except for three of four primary 
tumor cell cultures. 
 
 
 
 
                                  
samples 
mean of values
(pg/ml) 
TB853-EC 1026.4085 
TB846-EC 1885.082 
TB860-EC 698.9765 
TB426-PK 9833.766 
TB773-PK 2929.7645 
TB796-PK 8451.011 
TB863-PK 1803.284 
TB773-MSC 883.2235 
TB804-MSC 1721.488 
TB863-MSC 2028.277 
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4 Discussion 
 
Heat shock proteins, which are normally intracellularly localized conserved proteins, involved in 
folding and unfolding processes of proteins and peptides. Under physiological conditions, heat shock 
proteins might be involved in several processes including cell growth, differentiation and 
development (Lindquist and Craig, 1988). But under pathological conditions like cancer and 
inflammation, heat shock proteins could be highly expressed (Multhoff, 2007). They protect cells 
from lethal damage induced by stress stimuli like heat, hypoxia, radiotherapy and chemotherapy (De 
Maio, 1999). Hsp70 is a major inducible member of heat shock proteins in tumor cells, with the 
ability of protecting tumor cells from senescence (Yaglom et al., 2007). Recently, intracellular Hsp70 
was found to be translocated to the plasma membrane, where it interacts with glycosphingolipid Gb3 
and locates in cholesterol-rich domains (Gehrmann et al., 2008a; Vega et al., 2008). Further more, it 
was described to be secreted from intact tumor cells (Gehrmann et al., 2008a; Vega et al., 2008). 
 
Several studies analyzed the expression of intracellular Hsp70 in GBM cell lines and in tumor 
specimens from GBM patients (Hermisson et al., 2000). Intracellular Hsp70, which is detected by 
using specially targeting intracellular Hsp70 antibody, is expressed in a variety of GBM cell lines 
like U373MG, LN-18, LN-229, U138MG and heat shock treatment could enhance its expression 
(Hermisson et al., 2000). But there was no direct correlation between intracellular Hsp70 expression 
and radioresistance of glioma cell lines (Fedrigo et al., 2011) or clinical outcome of patients with 
GBMs (Hermisson et al., 2000). In the current study, immunohistochemistry showed no 
grade-dependent expression of intracellular Hsp70 in gliomas. These results are in line with already 
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published studies (Elsner et al., 2007; Hermisson et al., 2000), but membrane Hsp70 expression in 
gliomas was investigated for the first time in the current study. 
 
Membrane Hsp70 was detected on cell surface of a broad variety of human and mouse tumor cells in 
vitro and vivo, but not in non-neoplastic cells or normal tissues, thus served as a tumor-specific target 
structure (Multhoff, 2007; Multhoff and Hightower, 2011). The expression of membrane Hsp70 on 
tumor cells always served as “a danger signal” which might elicit antitumor immunity responses 
(Multhoff, 2007; Vega et al., 2008). In the plasma membrane of viable tumor cells, membrane Hsp70 
localized in cholesterol-rich domains (Gehrmann et al., 2008a; Stangl et al., 2011b). The team of 
Prof. Multhoff generated the cmHsp70.1 antibody by using human 14-er TKD sequence as specific 
immunogen (Multhoff and Hightower, 2011; Stangl et al., 2011a). This antibody could directly 
recognize the epitope of membrane bound form of heat shock protein 70 (Multhoff and Hightower, 
2011).  
 
In previous studies, membrane Hsp70 was found to uniquely be expressed on tumor cells and was 
detected by flow cytometry analysis on single-cell suspensions from different tumor entities but not 
from corresponding non-neoplastic entities in patients with colon, gastric, lower rectal and squamous 
cell lung cancer (Pfister et al., 2007). The reason why membrane Hsp70 was not expressed in 
non-neoplastic tissue could be due to the fact that ceramide-based glycosphingolipids including Gb3 
were not found in non-neoplastic cells (Gehrmann et al., 2008a). In such non-glial tumor entities, the 
membrane Hsp70-positive phenotype was associated with a higher metastatic potential and an 
unfavourable prognosis in malignant melanoma, acute myeloid leukaemia as well as lower rectal 
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carcinoma and lung squamous cell carcinoma (Farkas et al., 2003; Pfister et al., 2007). However, in 
colon and gastric cancer, membrane Hsp70 expression correlated with significant improved survival. 
The reason for these differing roles of membrane Hsp70 was supposed that the route of metastasis 
played a role, as colon and gastric tumor cells metastasize into the liver, where hepatic natural killer 
cells could provide a depletion of tumor cells (Pfister et al., 2007). In all mentioned tumors, 
membrane Hsp70-expression could be detected in the vast majority but not all tumor specimens 
(Pfister et al., 2007). For example, in head and neck cancer, the expression of membrane Hsp70 
differed in a broad range in the various tumor localizations (Kleinjung et al., 2003). The reason why 
some tumor specimens did not express membrane Hsp70 is still unknown (Kleinjung et al., 2003). 
In the current study, the immunohistochemical analysis showed that membrane Hsp70 expression 
was restricted to GBM tissues and could not be detected in non-neoplastic brains and WHO grade II 
or III astrocytomas. Surprisingly, membrane Hsp70 not only correlated with glioma grading but also 
differentiated secondary GBM from primary GBM. We found membrane Hsp70 positive signals in 
all of 23 primary GBM tissues, while in none of 13 secondary GBM tissues. 
As we know, there are several genes, serving as molecular markers, altered in gliomas and tend to 
occur in a defined order during the progression to a high-grade tumor, such as TP53, PTEN and 
EGFR (Ohgaki and Kleihues, 2007; Yan et al., 2009). In low-grade astrocytomas, the mutation of 
TP53 appeared to be a relatively early event, whereas loss or mutation of PTEN and amplification of 
EGFR were not observed. “Primary GBM and secondary GBM subtypes achieved a common 
phenotypic endpoint, but recent genomic profiles revealed strikingly different transcriptional 
patterns and recurrent DNA copy number aberrations” (Furnari et al., 2007). In primary GBMs, 
EGFR gene amplification occurred in 40% of primary GBMs (Libermann et al., 1985; Ohgaki and 
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Kleihues, 2007). One special form of EGFR, the EGFR mutant allele with deletion of exons 2-7 
(EGFRvIII), occurred in 20-30% of all human GBMs, making it to be the most common EGFR 
mutant (Nishikawa et al., 1994; Sugawa et al., 1990) and EGFR had been suggested as a prime target 
for therapeutic intervention in GBMs by using small molecule kinase inhibitors (Furnari et al., 2007; 
Huang et al., 2009). But as also mentioned, this marker was not a reliable marker for the 
characterization of a primary GBM due to its infrequent overexpression (Nishikawa et al., 1994; 
Ohgaki and Kleihues, 2007). In secondary GBMs, as present in 60% of precursor low-grade 
astrocytomas, TP53 mutation was the most frequently and detectable genetic alteration (Ohgaki and 
Kleihues, 2007), EGFR gene amplification was observed rarely in secondary GBMs (Libermann et 
al., 1985; Ohgaki and Kleihues, 2007). Recent studies showed that 70% of secondary GBMs had 
somatic mutations in the metabolic enzyme genes IDH1 (residue R132) and IDH2 (residue R172), 
but much more rarely primary GBM (5%) had such mutations (Watanabe et al., 2009; Yan et al., 
2009). The finding that IDH1 or IDH2 was mutated in the secondary GBMs provided a biologic 
explanation for the clinical categorization and compromised a specific subgroup of GBMs (Yan et al., 
2009). This genetic evidence suggested that IDH mutations were regarded as early genetic events in 
the tumor development of secondary GBM (Yan et al., 2009). IDH1 combined with EGFR, NF1, 
PDGFR genes were also used for subclassification of GBMs into proneural, neural, classical and 
mesenchymal subtypes (Verhaak et al., 2010). Also, many promoter methylation status of genes, like 
p16, p14, Rb1, TIMP-3, MGMT, were assessed in primary and secondary GBM (Ohgaki and 
Kleihues, 2007). For instance, O
6
-methylguanine methyltransferase (MGMT) promoter methylation 
was detected in 75% of secondary GBMs and 36% of primary GBMs (Nakamura et al., 2001), and 
the methylation status had reached clinical significance as it predicted the response of patients with 
 - 57 - 
GBMs to alkylating chemotherapeutic agents (Stupp et al., 2005). However, there was no marker 
which characterizes the more frequently existent primary GBM. As a result of the current study, 
immunohistochemistry of gliomas tissues showed a solitary expression of membrane Hsp70 in 
primary GBM but not in secondary GBM. This marker, membrane Hsp70, might serve as a reliable 
marker for primary GBM. 
 
In non-glial tumors, membrane Hsp70 was found to be a specific structure on tumor cells but not on 
other cell types (Multhoff, 2007). In GBM, the current study further distinguished the cellular 
subtypes within the heterogenous GBM cell conglomerate which expressed the membrane Hsp70, so 
distinct subpopulations including primary tumor cell cultures, CD133-positive cells, endothelial cells 
and mesenchymal stem-like cells were isolated from primary GBM tissues for checking membrane 
Hsp70 expression. In FACS-analysis results, selectively CD133-positive cells and primary tumor 
cell cultures expressed membrane Hsp70, which also could be expressed on GBM cell lines U87 and 
U373. CD133-positive cells were identified as a subpopulation of so-called cancer stem cells within 
glioblastoma tissue with an unlimited capacity for self-renewal and tumor-initiation (Chen et al., 
2010). Mesenchymal stem cells, which have the ability of homing to tumor tissue, differentiation in 
vitro and immunomodulatory potency (Motaln et al., 2010), and microvascular endothelial cells, 
which are involved in angiogenesis and vasculogenesis, did not express membrane Hsp70. As a 
consequence, it was supposed that the subpopulations with malignant potential including 
CD133-positive cells and primary tumor cell cultures express membrane Hsp70. So in GBM, the 
expression of membrane Hsp70 was also restricted to malignantly transformed cells such as 
CD133-positive cells, primary tumor cell cultures and GBM cell lines, which is in line with results 
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from other non-glial tumors (Multhoff, 2007). Heat shock proteins might have oncogene-like 
functions, for example, they could activate NF-ĸB which regulates several proteins that enhance 
tumor growth and tumor spreading (Sherman and Multhoff, 2007). Also, the regulation of heat shock 
proteins underlay oncogenic pathways such as TP53 pathway (Sherman and Multhoff, 2007). During 
transformation, genetic changes in cancers enhance the transcription of heat shock proteins and 
likewise stressed tumor cells must adapt to a hostile microenvironment for survival (Calderwood et 
al., 2006; Jego et al., 2010). This is thought to be reason why intracellular Hsp70 is translocated into 
plasma membrane and is secreted as exosomes in tumor cells (Gehrmann et al., 2008a; Vega et al., 
2008). 
 
On the other hand, in non-glial tumors, the expression of membrane Hsp70 could be enhanced by 
stress conditions as hypoxia and chemotherapeutic agents (Gehrmann et al., 2008a; Multhoff, 2007). 
For instance, in a leukemic cell line and colon carcinoma cell line, vincristine and paclitaxel 
compared to DNA-interacting antitumor agents (cytarabine, ifosfamid) increased not only the 
intracellular but also the membrane Hsp70 (Gehrmann et al., 2002). In other studies, the 
externalization of intracellular Hsp70 to the membrane-associated form under stress conditions 
serving as a “danger-signal” was investigated (Hightower and Guidon, 1989; Vega et al., 2008). So 
the effect of hypoxia on the expression of membrane Hsp70 was investigated in the current study. 
The isolated subpopulations from primary GBM, which have positive membrane Hsp70 expression, 
were cultured in hypoxia for 72h and determined by FACS for the change of membrane Hsp70 
expression. The results showed increased expressions of membrane Hsp70 were in primary tumor 
cell cultures and glioblastoma cell lines, but not in endothelial cells and mesenchymal stem-like cells, 
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which were recruited from the surrounding parenchyma or the host. The overexpression of 
membrane Hsp70 induced by hypoxia in vitro was confirmed by immunohistochemical staining of 
glioblastoma tissues. In consecutive immunostained slides, membrane Hsp70 expression was 
localized in the peri-necrotic hypoxic regions showing coexpression with the hypoxic marker Glut-1, 
but less in the well-vascularized areas. 
In glioma tissues, several molecules such as HIF-1α, Glut-1, CAIX, LDH-5, MCT1 and MCT4 are 
expressed and regulated by hypoxia, Glut-1 was supposed to be one of the most sensitive marker for 
hypoxia in gliomas (Rademakers et al., 2011; Vaupel and Mayer, 2007) and was also analyzed in the 
current study. In WHO grade II and III gliomas, Glut-1 staining could also be detected in 
endothelium of vessels and also in erythrocytes as it was previously described (Stockhammer et al., 
2008). In GBM, Glut-1-expression was found to be grade-dependently expressed and correlated with 
decreased survival in GBM patients (Flynn et al., 2008). As IDH might be involved in the oxidative 
decarboxylation of isocitrate to α-ketoglutarate which should result in an increased level of HIF-1α, 
the relationship between IDH mutation status and in-vivo hypoxic marker expression in WHO II and 
III gliomas was also analyzed (Metellus et al., 2011). But there was no correlation could be found 
between IDH-mutation status and in-vivo hypoxic markers as suspected, reflecting an adaptative 
behaviour of IDH-mutated glioma cells (Metellus et al., 2011; Williams et al., 2011). In addition, 
cancer cells were characterized by the “Warburg phenomenon”-producing energy predominantly by 
aerobic glycolysis in the cytosol, rather than by oxidation of pyruvate in mitochondria as in 
non-neoplastic cells (Warburg, 1956). IDH mutations in glioma cells could contribute to this 
phenomenon by changing metabolite pools and thereby facilitating glucose influx (Scott et al., 2011). 
During glioma progression, the glycolytic traits found in tumor cells might arise as adaptive 
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mechanisms to environmental constraints (Scott et al., 2011). 
 
Considering membrane Hsp70 can be secreted by membrane Hsp70 positive tumor cells in the form 
of exosomes (Multhoff and Hightower, 2011), membrane Hsp70 secretion in GBM was shown in 
this study for the first time. Conditioned media of subpopulations isolated from primary GBM were 
used to determine the concentration of membrane Hsp70 by ELISA with cmHsp70.1 antibody as 
capture antibody. In the line with FACS analysis results, only primary tumor cell cultures had high 
concentrations of membrane Hsp70. Three of four primary tumor cells cultures were detected to 
secrete more than 2000pg/ml membrane Hsp70 into conditioned medium. Endothelial cells and 
mesenchymal stem-like cells had significantly lower levels of membrane Hsp70, which were 
considered to be basic levels of membrane Hsp70 secretion. In order to find the clinical meanings of 
these in vitro results, serum samples of patients with primary and secondary GBM have been studied 
in this study with ELISA. Only in patients with primary GBM but not in secondary GBM or control 
epilepsy patients, membrane Hsp70 was highly secreted into bloodstream. Other groups combined 
extracellular Hsp70 with BMP20 and CXCL10 in a systematical research for indication of the 
presence of GBM (Elstner et al., 2011), but it was not possible to distinguish patients with primary 
GBM from secondary GBM by a single biomarker. In the current study, together with 
immunohistochemistry results, the results of membrane Hsp70 secreted into serum of patients with 
GBMs further suggested membrane Hsp70 might be a novel biomarker for the diagnosis of primary 
GBM.  
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   So in the current study, in gliomas, we concluded that membrane Hsp70 might serve as 
tumor-specific marker in primary GBM and could be used to differentiate the de-novo-origin from 
secondary GBM. There is more work needed to be done to assess the prognostic and predictive value 
of membrane Hsp70 in primary GBM. For instance, more tumor specimens and serum samples from 
patients with different grade gliomas should be included into further analysis; membrane Hsp70 
expression should be correlated with glioma progression, imaging findings, therapy responses, 
clinical outcome. On the other hand, although membrane Hsp70 expression on tumor cells can 
increase the immune response of natural killer cells or mediate the immunosuppressive function of 
myeloid-derived suppressive cells, the exact biological function of membrane Hsp70 has still to be 
elucidated. The process of Hsp70 translocate into plasma membrane during malignant 
transformation is not understood. Therefore, the biological function of membrane Hsp70 has to be 
further analyzed in order to tailor the treatment strategy of primary GBM. 
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5 Summary 
 
Glioma is the most frequent primary central nervous system cancer. Despite multimodal 
therapeutic strategies, glioblastoma is one of the tumor entities with a dismal prognosis for the 
patient. On the basis of genetic and biologic differences, glioblastoma can be divided into two 
distinct subtypes: primary and secondary glioblastoma. Up to now, there is no unique molecular 
marker which can be used to characterize the most frequently existent primary glioblastoma. On the 
other hand, membrane Hsp70 is shown to be expressed in a variety of non-glial human and mouse 
tumor cells in vitro and in vivo. Membrane Hsp70 is considered to be a tumour-specific target 
structure. 
In the current study, the expression of membrane Hsp70 in gliomas was investigated by using 
specifically targeting membrane Hsp70 antibody cmHsp70.1. In glioma tissues, membrane Hsp70 
was shown to be expressed only in primary glioblastoma, but not in normal brain, WHO grade II, III 
astrocytmoas or secondary glioblastoma. In primary glioblastoma tissue, membrane Hsp70 
expression was found to co-localize with hypoxia markers Glut-1 and HIF-1α. Moreover, membrane 
Hsp70 was shown to be expressed in primary tumor cell cultures and CD133 positive cells in a 
hypoxia-dependent manner, but not in endothelial cells or mesenchymal stem-like cells. On the 
clinical side, compared to patients with secondary glioblastoma, patients with primary glioblastoma 
showed higher concentrations of membrane Hsp70 in the serum.  
     So herein, the current study investigated the expression of membrane Hsp70 in gliomas and 
showed that membrane Hsp70 might serve as a novel, hypoxia-related marker for primary 
glioblastoma.  
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6 Zusammenfassung 
 
    Gliome sind die häufigsten primären hirneigenen Tumore. Trotz multimodalen therapeutischer 
Strategien ist das Glioblastom eine Tumorentität mit einer schlechten Prognose für den Patienten. 
Auf Grundlage der genetischen und biologischen Unterschiede können Glioblastome in zwei 
Subtypen unterteilt werden: primäre und sekundäre Glioblastome. Bis jetzt gibt es keinen 
eindeutigen molekularen Marker, der verwendet wird, um die am häufigsten vorhandenen primären 
Glioblastome zu charakterisieren. Auf der anderen Seite ist für membranständiges Hsp70 gezeigt 
worden, dass es in vielen nicht-Glia-Tumorzellen von Mensch und Maus in vitro und in vivo 
exprimiert wird. Membranständiges Hsp70 wird als tumor-spezifische Zielstruktur betrachtet. 
 
   In der aktuellen Studie wurde die Expression von membranständigem Hsp70 in Gliomen durch 
einen spezifischen anti-membranständiges Hsp70 Antikörper cmHsp70.1 untersucht. In 
Gliomgewebe wurde membranständiges Hsp70 nur im primären Glioblastom, aber nicht in 
normalem Gehirn, WHO-Grad II, III oder sekundären Glioblastomen exprimiert. Die Expression von 
membranständigem Hsp70 wurde in primären Glioblastomgewebe gefunden und co-lokalisierte mit 
Hypoxie Markern wie Glut-1 und HIF-1α. Darüber hinaus wurde gezeigt, dass membranständiges 
Hsp70 in Primärkulturen und CD133-positiven Zellen, die aus primären Glioblastomen isoliert 
wurden, exprimiert wird und durch Hypoxsie stimulier bar ist, aber nicht in Endothelzellen oder 
mesenchymalen Stammzell-artigen Zellen nachgewiesen wird. Auf der klinischen Seite, konnten wir 
zudem nachweisen, dass Patienten mit primärem Glioblastom höchere Konzentration von 
membranständigem Hsp70 im Serum als Patienten mit sekundären Glioblastomen. 
 
  In der aktuellen Studie wurde die Expression von membranstädigem Hsp70 in Gliomen untersucht.  
Es wurde gezeigt, dass membranständiges Hsp70 als neuartiger, Hypoxie-bezogener Marker für 
primäre Glioblastom dienen könnte. 
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7 Specific materials  
 
7.1 Chemicals and materials 
Chemical/material                            Company 
      Aceton                                Sigma-Aldrich, Germany 
      Bovine serum albumin(BSA)              Sigma-Aldrich, Germany 
      Dako immunohistochemistry kit            Dako, Germany 
      ELISA kit                             R&D systems, USA 
      Entellan                               Merck, Germany 
      Ficoll-paque gradient medium             Biochrom, Germany 
            Matrigel                               BD Biosciences, Germany 
            Haematoxylin                          Merck, Germany 
      Isopropanol                            Merck, Germany 
      Propidium iodide                        Applichem, Germany 
      Tween20                              Applichem, Germany 
      Trypsin/EDTA                         Sigma-Aldrich, Germany 
      Oil Red S                             Sigma-Aldrich, Germany 
7.2 Cell culture 
    Component                                 Company 
B27                                  Invitrogen, USA 
Beta-glycerophosphate                   Fluka, Switzerland 
Dexamethason                         Sigma-Aldrich, Germany 
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DMEM                               Biochrom, Germany 
DMEM/F12                            Invitrogen, USA 
FCS                                  Biochrom, Germany 
FGF                                  R&D systems, Germnay    
Human EGF                            R&D systems, Germany 
N2                                   Invitrogen, USA 
Non-essential amino acids                 Invitrogen, USA 
Penicillin/Streptomycin/Glutamine          Invitrogen, USA 
L-ascorbic acid                         Sigma-Aldrich, Germany 
Isobutylmethylxanthine                   Sigma-Aldrich, Germany 
Indomethacin                           Sigma-Aldrich, Germany 
Insulin                                Sigma-Aldrich, Germany 
Microvascular endothelial cell growth medium  
                                      Provitro, Germany 
7.3 Equipments and buffers 
         Equipment                                  Company 
     Dynabeads magnetic beads                       Dynabeads, Germany 
     FACS Calibur Flowcytometer                     BD Biosciences, USA 
     MACS column                                 Miltenyi Biotech, Germany 
     Hypoxia incubator                              Binder Brutschrank, Germany 
Ibidi angiogenesis slides                          ibidi GmbH, Germany 
Plastic flasks                                   Nunc, Germany 
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PBS puffer  10x 
         NaCl                      87.7g 
         Na2HPO4                  11.7g 
         KCL                       2g 
         KH2PO4                   2.4g 
         ddH20  to 1000ml 
        Adjust PH to 7.4                       
 
 TBS puffer 
     Tris                      50mM 
     NaCl                     150Mm 
     Adjust PH to 7.6 
 FACS puffer 
1x PBS  
 10% FCS 
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